Literature DB >> 20506373

Novel immunogenic antigens increase classification accuracy in meningioma to 93.84%.

Nicole Ludwig1, Andreas Keller, Sabrina Heisel, Petra Leidinger, Stefanie Rheinheimer, Claudia Andres, Bernhard Stephan, Wolf-Ingo Steudel, Erich Donauer, Norbert Graf, Bernhard Burgeth, Joachim Weickert, Hans-Peter Lenhof, Eckart Meese.   

Abstract

There is growing evidence that simultaneous analysis of multiple autoantibody reactions can be utilized for diagnosis of neoplasms. Using a set of 57 meningioma-associated antigens, we recently separated meningioma patients from individuals without known disease with an accuracy of 90.3%. Here, we ask whether a largely increased set of immunogenic antigens can further improve this discrimination. We used an array with 1,827 human recombinant clones and measured reactivity of serum autoantibodies against the clones by a novel automated image analysis procedure. We were able to separate meningioma sera from sera of healthy controls with a specificity of 95.62%, a sensitivity of 91.83% and an accuracy of 93.84%. Of the analyzed clones, 23 in-frame clones were highly informative for the classification of meningioma vs. normal sera as shown by their AUC values. These results demonstrate that the accuracy of a serum-based diagnostic can be readily and considerably improved by screening extended sets of proteins.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20506373     DOI: 10.1002/ijc.25467

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Immunogenicity of autoantigens.

Authors:  Christina Backes; Nicole Ludwig; Petra Leidinger; Christian Harz; Jana Hoffmann; Andreas Keller; Eckart Meese; Hans-Peter Lenhof
Journal:  BMC Genomics       Date:  2011-07-04       Impact factor: 3.969

2.  Serum autoantibodies to pancreatic cancer antigens as biomarkers of pancreatic cancer in a San Francisco Bay Area case-control study.

Authors:  Paige M Bracci; Mi Zhou; Scott Young; Joseph Wiemels
Journal:  Cancer       Date:  2012-04-19       Impact factor: 6.860

3.  Reduced allergy and immunoglobulin E among adults with intracranial meningioma compared to controls.

Authors:  Joseph L Wiemels; Margaret Wrensch; Jennette D Sison; Mi Zhou; Melissa Bondy; Lisa Calvocoressi; Peter M Black; Herbert Yu; Joellen M Schildkraut; Elizabeth B Claus
Journal:  Int J Cancer       Date:  2011-04-25       Impact factor: 7.396

4.  Assessment of autoantibodies to meningioma in a population-based study.

Authors:  Joseph L Wiemels; Paige M Bracci; Margaret Wrensch; Joellen Schildkraut; Melissa Bondy; Jon Pfefferle; Mi Zhou; Jennette Sison; Lisa Calvocoressi; Elizabeth B Claus
Journal:  Am J Epidemiol       Date:  2012-12-06       Impact factor: 4.897

5.  Identification of novel SNPs in glioblastoma using targeted resequencing.

Authors:  Andreas Keller; Christian Harz; Mark Matzas; Benjamin Meder; Hugo A Katus; Nicole Ludwig; Ulrike Fischer; Eckart Meese
Journal:  PLoS One       Date:  2011-06-10       Impact factor: 3.240

6.  Autoantibody signature differentiates Wilms tumor patients from neuroblastoma patients.

Authors:  Jana Schmitt; Andreas Keller; Nasenien Nourkami-Tutdibi; Sabrina Heisel; Nunja Habel; Petra Leidinger; Nicole Ludwig; Manfred Gessler; Norbert Graf; Frank Berthold; Hans-Peter Lenhof; Eckart Meese
Journal:  PLoS One       Date:  2011-12-16       Impact factor: 3.240

7.  Evaluation of autoantibody signatures in meningioma patients using human proteome arrays.

Authors:  Shabarni Gupta; Shuvolina Mukherjee; Parvez Syed; Narendra Goud Pandala; Saket Choudhary; Vedita Anand Singh; Namrata Singh; Heng Zhu; Sridhar Epari; Santosh B Noronha; Aliasgar Moiyadi; Sanjeeva Srivastava
Journal:  Oncotarget       Date:  2017-04-10

8.  Myasthenia gravis: analysis of serum autoantibody reactivities to 1827 potential human autoantigens by protein macroarrays.

Authors:  Anne Becker; Nicole Ludwig; Andreas Keller; Björn Tackenberg; Christian Eienbröker; Wolfgang H Oertel; Klaus Fassbender; Eckart Meese; Klemens Ruprecht
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.